ESMO Preceptorship on Prostate Cancer Lugano 2016

Oncology Meeting Resources

11 Nov - 12 Nov, Lugano, Switzerland

ESMO Preceptorship on Prostate Cancer

Main learning objectives for the ESMO Preceptorship on Prostate Cancer Lugano 2016 included learning about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer; understanding essentials in the assessments and multidisciplinary treatment of prostate cancer and learning about advances in treatment and novel targets in prostate cancer.

Presentations from the Preceptorship are now available here. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links

Presenter Presentation title Session title
A. Horwich, UK Welcome From ESMO - Objectives and Scientific Introduction Opening and Welcome
N. Mottet, FR PSA Screening and Diagnosis Session 1 - Screening, Diagnosis and Staging
F. Algaba, ES Diagnosis and Impact of Pathology on Prognosis Session 1 - Screening, Diagnosis and Staging
N. Mottet, FR Imaging Tests and Staging Classification Session 1 - Screening, Diagnosis and Staging
V. Fonteyne, BE Role of Radiotherapy Session 2 - Localized Prostate Cancer
N. Mottet, FR Role of Surgery Session 2 - Localized Prostate Cancer
A. Horwich, UK Active Surveillance Session 2 - Localized Prostate Cancer
G. Botiralieva, UZ Participants Clinical Case Discussion: Clinical Case Discussion: Metastatic Castration – Resistant Prostate Cancer Session 2 - Localized Prostate Cancer
A. Martynchyk, UA Participants Clinical Case Discussion: Importance of PSA Screening Session 2 - Localized Prostate Cancer
N. Mottet, FR Presentation With Lymphadenopathy Session 3 - Locally-Advanced Prostate Cancer
N. Mottet, FR Managing Urinary Obstruction Session 3 - Locally-Advanced Prostate Cancer
V. Fonteyne, BE Debate: This House Believes That Locally-Advanced Prostate Cancer Should be Treated With Radiotherapy and Hormone Deprivation - Argument For Session 3 - Locally-Advanced Prostate Cancer
N. Mottet, FR Debate: This House Believes That Locally-Advanced Prostate Cancer Should be Treated With Radiotherapy and Hormone Deprivation - Argument Against Session 3 - Locally-Advanced Prostate Cancer
E. Castro, ES Value and Role of PSA as a Tumour Marker of Response/Relapse Session 3 - Locally-Advanced Prostate Cancer
A. Nemes, RO Participants Clinical Case Discussion: Treatment in Aggressive Locally Advanced Prostate Cancer Session 3 - Locally-Advanced Prostate Cancer